Human papillomavirus-related genital disease in the immunocompromised host: Part II

J Am Acad Dermatol. 2012 Jun;66(6):883.e1-17; quiz 899-900. doi: 10.1016/j.jaad.2010.12.049.

Abstract

Human papillomavirus is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. The immunocompromised population is at particular risk because of a higher incidence of malignant transformation. Lesions in this population may prove refractory to standard treatment. This is part II of a two-part review that will discuss the treatment of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias. This article will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating human papillomavirus lesions in the immunocompromised host.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use
  • Alphapapillomavirus*
  • Aminoquinolines / administration & dosage
  • Aminoquinolines / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Anus Neoplasms
  • Buschke-Lowenstein Tumor
  • Catechin / analogs & derivatives
  • Catechin / therapeutic use
  • Caustics / therapeutic use
  • Cidofovir
  • Condylomata Acuminata / therapy
  • Counseling
  • Cryotherapy
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • Female
  • Humans
  • Imiquimod
  • Immunocompromised Host*
  • Male
  • Ointments
  • Organophosphonates / therapeutic use
  • Papillomavirus Infections / drug therapy
  • Papillomavirus Infections / therapy*
  • Penile Neoplasms / immunology
  • Penile Neoplasms / therapy*
  • Penile Neoplasms / virology
  • Podophyllotoxin / therapeutic use
  • Precancerous Conditions
  • Treatment Outcome
  • Trichloroacetic Acid / therapeutic use
  • Vaginal Neoplasms / immunology
  • Vaginal Neoplasms / therapy*
  • Vaginal Neoplasms / virology
  • Vulvar Neoplasms / immunology
  • Vulvar Neoplasms / therapy*
  • Vulvar Neoplasms / virology
  • Warts / immunology
  • Warts / therapy*
  • Warts / virology

Substances

  • Adjuvants, Immunologic
  • Aminoquinolines
  • Antineoplastic Agents, Phytogenic
  • Antiviral Agents
  • Caustics
  • Ointments
  • Organophosphonates
  • Trichloroacetic Acid
  • Cytosine
  • Catechin
  • Cidofovir
  • Podophyllotoxin
  • Imiquimod
  • polyphenon E